by Brad N. Taylor, Ph.D. | Apr 6, 2022
Scaling up cell culture media for your cellular therapy doesn’t have to be grueling; Nucleus Biologics simplifies formulation testing, scale-up, and re-ordering to make your life easier. Last week, we discussed media potency and how changing even one cell culture...
by Brad N. Taylor, Ph.D. | Mar 23, 2022
Nucleus Biologics to distribute a groundbreaking cell culture media system, Krakatoa™, which is designed to deliver high-quality, custom-made cell culture media at its maximum potency. Last week, we introduced the 4 pillars that form the foundation of Krakatoa™, a...
by Brad N. Taylor, Ph.D. | Mar 8, 2022
Nucleus Biologics recently announced the distribution of Krakatoa™, a point-of-use media manufacturing system aimed at improving the industry’s environmental impact. Nucleus Biologics plans to cure people + planet. Not many biologics companies have such bold goals,...
by Brad N. Taylor, Ph.D. | Feb 8, 2022
Age-related macular degeneration (AMD) is the degeneration/dysregulation of cells of the retinal pigment epithelium (RPE) and is the most common cause of severe loss of central vision among people 50 and older, affecting approximately 200 million people worldwide [1]....
by Brad N. Taylor, Ph.D. | Jan 20, 2022
Cytiva welcomes Nucleus Biologics’ proven and powerful AI-powered interface that brings state-of-the-art cell media design and supply to the Cell and Gene Therapy Industry. Cell and gene therapies are critically reliant on the growth and maintenance of a viable and...
by Brad N. Taylor, Ph.D. | Jan 18, 2022
Getting Attached In the final part of this 3-part blog series, Defining the undefined with Vitronectin XF™, get attached to Vitronectin even more as we delve into the performance data. In our previous blogs, we discussed how mixed extracellular matrix (ECM) gels such...
